Complete financial analysis of Tenaya Therapeutics, Inc. (TNYA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tenaya Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Balkrishna Industries Limited (BALKRISIND.NS) Income Statement Analysis – Financial Results
- The State Trading Corporation of India Limited (STCINDIA.BO) Income Statement Analysis – Financial Results
- Marley Spoon Group SE (MS1.DE) Income Statement Analysis – Financial Results
- Bloomsbury Publishing Plc (BMY.L) Income Statement Analysis – Financial Results
- Glenmark Life Sciences Limited (GLS.NS) Income Statement Analysis – Financial Results
Tenaya Therapeutics, Inc. (TNYA)
About Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 8.69M | 8.71M | 4.03M | 2.48M | 1.99M |
| Gross Profit | -8.69M | -8.71M | -4.03M | -2.48M | -1.99M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 98.04M | 94.54M | 54.39M | 31.10M | 23.15M |
| General & Administrative | 33.16M | 31.08M | 18.41M | 7.81M | 4.56M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 33.16M | 31.08M | 18.41M | 7.81M | 4.56M |
| Other Expenses | 0.00 | 2.00K | -23.00K | 430.00K | 1.03M |
| Operating Expenses | 131.19M | 125.62M | 72.81M | 38.91M | 27.71M |
| Cost & Expenses | 131.19M | 125.62M | 72.81M | 38.91M | 27.71M |
| Interest Income | 7.06M | 1.95M | 108.00K | 87.00K | 453.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.69M | 8.71M | 4.03M | 2.48M | 1.99M |
| EBITDA | -122.51M | -114.95M | -68.70M | -36.43M | -25.72M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -131.19M | -125.62M | -72.81M | -38.91M | -27.71M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.11M | 1.96M | 85.00K | 517.00K | 1.48M |
| Income Before Tax | -124.08M | -123.67M | -72.72M | -38.40M | -26.23M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.96K | -3.07M | -87.00K | -453.00K |
| Net Income | -124.08M | -123.66M | -69.65M | -38.31M | -25.78M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.68 | -2.76 | -1.69 | -0.93 | -0.63 |
| EPS Diluted | -1.68 | -2.76 | -1.69 | -0.93 | -0.63 |
| Weighted Avg Shares Out | 73.79M | 44.82M | 41.29M | 41.12M | 41.12M |
| Weighted Avg Shares Out (Dil) | 73.79M | 44.82M | 41.29M | 41.12M | 41.12M |
4 Penny Stocks To Buy In January According To Insiders
5 Penny Stocks To Buy According To Analysts, Targets Up To 992%
Tenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ESGCT 29th Annual Congress
Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics
Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference
Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference
Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
Tenaya Therapeutics to Present Preclinical Data on Gene Therapy Programs and Platform Capabilities at the American Society of Gene and Cell Therapy 25th Annual Meeting
Tenaya Therapeutics to Present Preclinical Data on TN-401 PKP2 Gene Therapy Program at Heart Rhythm 2022
Tenaya Therapeutics to Participate in Upcoming Investor Conferences
Source: https://incomestatements.info
Category: Stock Reports